Cargando…

A Novel Fusion Protein System for the Production of Nanobodies and the SARS-CoV-2 Spike RBD in a Bacterial System

Antibodies are key proteins of the immune system, and they are widely used for both research and theragnostic applications. Among them, camelid immunoglobulins (IgG) differ from the canonical human IgG molecules, as their light chains are completely missing; thus, they have only variable domains on...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagy-Fazekas, Dóra, Stráner, Pál, Ecsédi, Péter, Taricska, Nóra, Borbély, Adina, Nyitray, László, Perczel, András
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10045489/
https://www.ncbi.nlm.nih.gov/pubmed/36978780
http://dx.doi.org/10.3390/bioengineering10030389
_version_ 1784913615674933248
author Nagy-Fazekas, Dóra
Stráner, Pál
Ecsédi, Péter
Taricska, Nóra
Borbély, Adina
Nyitray, László
Perczel, András
author_facet Nagy-Fazekas, Dóra
Stráner, Pál
Ecsédi, Péter
Taricska, Nóra
Borbély, Adina
Nyitray, László
Perczel, András
author_sort Nagy-Fazekas, Dóra
collection PubMed
description Antibodies are key proteins of the immune system, and they are widely used for both research and theragnostic applications. Among them, camelid immunoglobulins (IgG) differ from the canonical human IgG molecules, as their light chains are completely missing; thus, they have only variable domains on their heavy chains (VHHs). A single VHH domain, often called a nanobody, has favorable structural, biophysical, and functional features compared to canonical antibodies. Therefore, robust and efficient production protocols relying on recombinant technologies are in high demand. Here, by utilizing ecotin, an Escherichia coli protein, as a fusion partner, we present a bacterial expression system that allows an easy, fast, and cost-effective way to prepare nanobodies. Ecotin was used here as a periplasmic translocator and a passive refolding chaperone, which allowed us to reach high-yield production of nanobodies. We also present a new, easily applicable prokaryotic expression and purification method of the receptor-binding domain (RBD) of the SARS-CoV-2 S protein for interaction assays. We demonstrate using ECD spectroscopy that the bacterially produced RBD is well-folded. The bacterially produced nanobody was shown to bind strongly to the recombinant RBD, with a K(d) of 10 nM. The simple methods presented here could facilitate rapid interaction measurements in the event of the appearance of additional SARS-CoV-2 variants.
format Online
Article
Text
id pubmed-10045489
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100454892023-03-29 A Novel Fusion Protein System for the Production of Nanobodies and the SARS-CoV-2 Spike RBD in a Bacterial System Nagy-Fazekas, Dóra Stráner, Pál Ecsédi, Péter Taricska, Nóra Borbély, Adina Nyitray, László Perczel, András Bioengineering (Basel) Article Antibodies are key proteins of the immune system, and they are widely used for both research and theragnostic applications. Among them, camelid immunoglobulins (IgG) differ from the canonical human IgG molecules, as their light chains are completely missing; thus, they have only variable domains on their heavy chains (VHHs). A single VHH domain, often called a nanobody, has favorable structural, biophysical, and functional features compared to canonical antibodies. Therefore, robust and efficient production protocols relying on recombinant technologies are in high demand. Here, by utilizing ecotin, an Escherichia coli protein, as a fusion partner, we present a bacterial expression system that allows an easy, fast, and cost-effective way to prepare nanobodies. Ecotin was used here as a periplasmic translocator and a passive refolding chaperone, which allowed us to reach high-yield production of nanobodies. We also present a new, easily applicable prokaryotic expression and purification method of the receptor-binding domain (RBD) of the SARS-CoV-2 S protein for interaction assays. We demonstrate using ECD spectroscopy that the bacterially produced RBD is well-folded. The bacterially produced nanobody was shown to bind strongly to the recombinant RBD, with a K(d) of 10 nM. The simple methods presented here could facilitate rapid interaction measurements in the event of the appearance of additional SARS-CoV-2 variants. MDPI 2023-03-22 /pmc/articles/PMC10045489/ /pubmed/36978780 http://dx.doi.org/10.3390/bioengineering10030389 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Nagy-Fazekas, Dóra
Stráner, Pál
Ecsédi, Péter
Taricska, Nóra
Borbély, Adina
Nyitray, László
Perczel, András
A Novel Fusion Protein System for the Production of Nanobodies and the SARS-CoV-2 Spike RBD in a Bacterial System
title A Novel Fusion Protein System for the Production of Nanobodies and the SARS-CoV-2 Spike RBD in a Bacterial System
title_full A Novel Fusion Protein System for the Production of Nanobodies and the SARS-CoV-2 Spike RBD in a Bacterial System
title_fullStr A Novel Fusion Protein System for the Production of Nanobodies and the SARS-CoV-2 Spike RBD in a Bacterial System
title_full_unstemmed A Novel Fusion Protein System for the Production of Nanobodies and the SARS-CoV-2 Spike RBD in a Bacterial System
title_short A Novel Fusion Protein System for the Production of Nanobodies and the SARS-CoV-2 Spike RBD in a Bacterial System
title_sort novel fusion protein system for the production of nanobodies and the sars-cov-2 spike rbd in a bacterial system
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10045489/
https://www.ncbi.nlm.nih.gov/pubmed/36978780
http://dx.doi.org/10.3390/bioengineering10030389
work_keys_str_mv AT nagyfazekasdora anovelfusionproteinsystemfortheproductionofnanobodiesandthesarscov2spikerbdinabacterialsystem
AT stranerpal anovelfusionproteinsystemfortheproductionofnanobodiesandthesarscov2spikerbdinabacterialsystem
AT ecsedipeter anovelfusionproteinsystemfortheproductionofnanobodiesandthesarscov2spikerbdinabacterialsystem
AT taricskanora anovelfusionproteinsystemfortheproductionofnanobodiesandthesarscov2spikerbdinabacterialsystem
AT borbelyadina anovelfusionproteinsystemfortheproductionofnanobodiesandthesarscov2spikerbdinabacterialsystem
AT nyitraylaszlo anovelfusionproteinsystemfortheproductionofnanobodiesandthesarscov2spikerbdinabacterialsystem
AT perczelandras anovelfusionproteinsystemfortheproductionofnanobodiesandthesarscov2spikerbdinabacterialsystem
AT nagyfazekasdora novelfusionproteinsystemfortheproductionofnanobodiesandthesarscov2spikerbdinabacterialsystem
AT stranerpal novelfusionproteinsystemfortheproductionofnanobodiesandthesarscov2spikerbdinabacterialsystem
AT ecsedipeter novelfusionproteinsystemfortheproductionofnanobodiesandthesarscov2spikerbdinabacterialsystem
AT taricskanora novelfusionproteinsystemfortheproductionofnanobodiesandthesarscov2spikerbdinabacterialsystem
AT borbelyadina novelfusionproteinsystemfortheproductionofnanobodiesandthesarscov2spikerbdinabacterialsystem
AT nyitraylaszlo novelfusionproteinsystemfortheproductionofnanobodiesandthesarscov2spikerbdinabacterialsystem
AT perczelandras novelfusionproteinsystemfortheproductionofnanobodiesandthesarscov2spikerbdinabacterialsystem